Calendario›SNY›AD-impaCT

AD-impaCT

A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries

Ensayo de Sanofi en Dermatitis Atopic (del registro, en inglés).

Fase

no aplica

Estado

Completado

Participantes

187

previstos

Centros

3

Fin del objetivo primario

mar 2023

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en ene 2022.

Qué mide

Percentage of patients achieving an Atopic Dermatitis Control Tool (ADCT) score less than 7 (defined as in control according to ADCT) (del registro, en inglés) (en la semana 24)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPrimary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment. Secondary objectives: * To figure the proportion of patients with reduction of ADCT score by 5 points after 4, 12, and 24 weeks of treatment. * To figure the proportion of patients with ADCT score less than 7 at weeks 4, 12, and 24. * Assess the effectiveness of dupilumab in moderate to severe atopic dermatitis (AD) patients, using the severity score as routine practice SCORing Atopic Dermatitis (SCORAD). * To describe comorbidities related to type 2 inflammation. * To characterize the safety profile of dupilumab in the local Gulf population. * To evaluate treatment satisfaction in the local Gulf population.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05214326), actualizada en nov 2023.